Parenteral Nutrition Market accounted for US$ 5.90 billion in 2020 and is estimated to be US$ 10.33 million by 2030 and is anticipated to register a CAGR of 5.8%. Parenteral nutrition (PN) is the intravenous administration of nutrition, which can include protein, carbohydrate, fat, minerals and electrolytes, vitamins, and other trace elements, to patients who are unable to eat or absorb enough food through tube feeding formula or by mouth to maintain a healthy nutritional status. When the intestine is unable to absorb enough nutrients for your child to grow and develop appropriately, parenteral feeding is employed. A liquid solution containing nutrients for growth and development (vitamins, minerals, carbs, proteins, and lipids) is injected straight into a vein.
The report ” Global Parenteral Nutrition Market, By Nutrition Type (Single Dose Amino Acid Solution, Carbohydrates, Parenteral Lipid Emulsion, Trace Elements, and Vitamins & Minerals) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Trends, Analysis and Forecast Till 2029’’
In September 2019, EFCNI proudly announces the launch of their position paper “Addressing the nutritional emergency of preterm birth – Optimal practice in neonatal parenteral nutrition”.
In August 2019, JW Life Science said that Baxter Pharmaceutical, its European partner, has launched Finomel, a ready-to-use triple-chamber bag for parenteral nutrition (PN), in EU. Finomel is a third-generation nutrient solution that ideally combines omega-3 and omega-6, which promote patient recovery, and vitamin E, thus improving immunity. The product also contains the highest omega-3 content among the three-chamber PN products currently sold in the market.
To know the upcoming trends and insights prevalent in this market, click the link below:
The key players operating in the global Parenteral Nutrition Market includes Actavis, Inc., Aculife, Healthcare Private Ltd. , Baxter International, Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Hospira, Inc., Grifols International S.A., Otsuka Pharmaceutical Factory, Inc., Sichuan Kelun Pharmaceutical Co. Ltd. and Vifor Pharma.